MIRA INFORM REPORT

 

 

Report No. :

341078

Report Date :

18.09.2015

 

IDENTIFICATION DETAILS

 

Name :

APEX DRUGS AND INTERMEDIATES LIMITED (w.e.f. 04.03.1996)

 

 

Formerly Known As :

APEX DRUGS AND INTERMEDIATES PRIVATE LIMITED

 

AGANI SYNTHETICS PRIVATE LIMTIED

 

 

Registered Office :

210, 2nd Floor, Ram’s Enclave, Erragadda, Hyderabad – 500018, Telangana

Tel. No.:

91-40-23706034/ 23717365/ 23717366

 

 

Country :

India

 

 

Financials (as on) :

31.03.2014

 

 

Date of Incorporation :

05.12.1989

 

 

Com. Reg. No.:

36-010737

 

 

Capital Investment / Paid-up Capital :

Rs. 110.764  Million

 

 

CIN No.:

[Company Identification No.]

U24230TG1989PLC010737

 

 

IEC No.:

0990004732

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

Not Available

 

 

PAN No.:

[Permanent Account No.]

AABCA7175J

 

 

Legal Form :

A Closely Held Public Limited Liability Company

 

 

Line of Business :

Manufacturer and Exporter of pharmaceutical ingredients including active pharmaceutical ingredients and drug intermediates.

 

 

No. of Employees :

Not Divulged

 

 

RATING & COMMENTS

 

MIRA’s Rating :

B (27)

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Maximum Credit Limit :

USD 1500000

 

 

Status :

Moderate

 

 

Payment Behaviour :

Slow but correct

 

 

Litigation :

Clear

 

 

Comments :

Subject is an established company incorporated during the year 1989. It has moderate track.

 

For the year ended, the company had average operational activity. It has reported decrease in 2014 its revenue along with continuous loses.

 

The rating is constrained on account of company’s moderate financial risk profile marked modest networth position and huge borrowings taken by the company.

 

However, trade relations are fair. Business is active. Payments are slow but correct.

 

The company can be considered for business dealings with some caution. 

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31, 2015

 

Country Name

Previous Rating

(31.12.2014)

Current Rating

(31.03.2015)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

EXTERNAL AGENCY RATING

 

 

Rating Agency Name

ICRA

Rating

Long Term Rating “BBB” (Suspended)

Rating Explanation

Moderate degree of safety and moderate credit risk

Date

March 2013

 

Rating Agency Name

ICRA

Rating

Short Term Rating “A3” (Suspended)

Rating Explanation

Moderate degree of safety and higher credit risk

Date

March 2013

 

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2015.

 

 

 

INFORMATION PARTED BY (PARTIAL DETAILS)

 

Name :

Mr. Suresh

Designation :

Accountant

Contact No.:

91-40-23706034

Date :

15.09.2015

 

 

LOCATIONS

 

Registered Office :

210, 2nd Floor, Ram’s Enclave, Erragadda, Hyderabad – 500018, Telangana, India 

Tel. No.:

91-40-23706034/ 23717365/ 23717366

Fax No.:

91-40-23707368

E-Mail :

gskurmi@yahoo.com

marketing@apexdrugs.net

purchase@apexdrugs.net

accounts@apexdrugs.net

gskurmi@apexdrugs.net

apex@apexdrug.net

Website :

www.apexdrugs.net

 

 

Factory :

Survey No.14, Gadda Potharam Industrial Area, Jinnaram Mandal, District Medak, Andhra Pradesh, India

Tel. No.:

91-8458-277268/ 277036

Fax No.:

91-8458-277263

Location:

Owned

 

 

DIRECTORS

 

As on 30.09.2014

 

Name :

Mr. Ghanshyam Surajbali Kurmi

Designation :

Managing Director

Address :

201, Shilpa Manor, Next to Savera Function Hall, Yousufguda, Hyderabad – 500045, Telangana, India 

Date of Birth/Age :

11.08.1969

Date of Appointment :

01.06.2011

DIN No.:

00046169

Other Directorship :

S. No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Date of cessation

Company/ LLP Status

Defaulting status

1

U74140MH2006PTC160780

MAGHAN FINANCIAL SERVICES PRIVATE LIMITED

Director

01/10/2009

28/03/2006

-

Active

NO

2

U67110MH2006PTC160857

KUMKUM FINANCIAL SERVICES PRIVATE LIMITED

Director

01/10/2009

30/03/2006

-

Active

NO

3

U24230TG1989PLC010737

APEX DRUGS AND INTERMEDIATES LIMITED

Managing director

01/06/2011

21/04/2006

-

Active

NO

4

U67100TG2009PTC065037

INDRADHANUSH FINANCIAL SERVICES PRIVATE LIMITED

Director

11/09/2009

11/09/2009

-

Active

NO

5

U67190TG2009PTC065159

EXHILARATION FINANCIAL SERVICES PRIVATE LIMITED

Director

22/09/2009

22/09/2009

-

Active

NO

6

U24232TG2010PTC069053

SUNRIDGE PHARMACEUTICALS PRIVATE LIMITED

Additional director

01/04/2013

01/04/2013

-

Active

NO

 

 

Name :

Mr. Gangapalli Ravi

Designation :

Whole Time Director

Address :

Lig 531 Ramachandrapuram, Hyderabad - 500032, Telangana, India

Date of Birth/Age :

13.05.1963

Date of Appointment :

05.02.2015

DIN No.:

03010397

Other Directorship :

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Date of cessation

Company/ LLP Status

Defaulting status

1

U24233TG2010PTC068070

COASTAL LIFE SCIENCES PRIVATE LIMITED

DIRECTOR

23/04/2010

23/04/2010

30/11/2011

Active

NO

2

U24230TG1989PLC010737

APEX DRUGS AND INTERMEDIATES LIMITED

WHOLE-TIME DIRECTOR

05/02/2015

05/02/2015

-

Active

NO

 

 

Name :

Mr. Sandeep Kumar Verma

Designation :

Additional Director

Address :

210, Rams Enclave, Erragadda, Hyderabad-500018, Andhra Pradesh, India 

Date of Birth/Age :

12.08.1987

Date of Appointment :

01.03.2010

DIN No.:

02808834

Other Directorship :

S. No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Date of cessation

Company/ LLP Status

Defaulting status

1

U67190TG2009PTC065159

EXHILARATION FINANCIAL SERVICES PRIVATE LIMITED

ADDITIONAL DIRECTOR

30/11/2009

30/11/2009

01/02/2012

Active

NO

2

U67100TG2009PTC065037

INDRADHANUSH FINANCIAL SERVICES PRIVATE LIMITED

ADDITIONAL DIRECTOR

30/11/2009

30/11/2009

01/02/2012

Active

NO

3

U74140MH2006PTC160780

MAGHAN FINANCIAL SERVICES PRIVATE LIMITED

DIRECTOR

16/01/2010

16/01/2010

01/02/2012

Active

NO

4

U67110MH2006PTC160857

KUMKUM FINANCIAL SERVICES PRIVATE LIMITED

DIRECTOR

16/01/2010

16/01/2010

01/02/2012

Active

NO

5

U24230TG1989PLC010737

APEX DRUGS AND INTERMEDIATES LIMITED

ADDITIONAL DIRECTOR

01/03/2010

01/03/2010

-

Active

NO

 

 

KEY EXECUTIVES

 

Name :

Mr. Suresh

Designation :

Accountant 

 

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

As on 30.09.2014

 

Names of Shareholders

No. of Shares

Ghanshyam S. Kurmi

11075211

Maghan Financial Services Private Limited, India

200

Kumkum Financial Services Private Limited, India

200

K. Sudhakar Reddy

200

G Shekhar Reddy

200

Ashok Vsudevan

200

Gaurav Singh

200

Total

11076411

 

Equity Share Break up (Percentage of Total Equity)

 

As on 30.09.2014

 

Category

Percentage

Bodies Corporate

 

Directors or relatives of Directors

0.0036

 

99.9964

Total

100.00

 

 

 

 

 

 

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturer and Exporter of pharmaceutical ingredients including active pharmaceutical ingredients and drug intermediates.

 

 

Products :

Item Code No.

Product Description

29420032

Clopidogrel Bi Sulphate

 

 

Brand Names :

Not Available

 

 

Agencies Held :

Not Available

 

 

Exports :

Not Divulged

 

 

Imports :

Not Divulged

 

 

Terms :

 

Selling :

L/C and Cheque

 

 

Purchasing :

L/C and Cheque

 

PRODUCTION STATUS NOT AVAILABLE

 

GENERAL INFORMATION

 

Suppliers :

Reference :

Not Divulged

Name of the Person :

Not Divulged

Contact No.:

Not Divulged

Since How Long Known :

Not Divulged

Maximum Limit Dealt :

Not Divulged

Experience :

Not Divulged

Remark:

Not Divulged

 

 

Customers :

Retailers, End Users

Reference :

Not Divulged

Name of the Person :

Not Divulged

Contact No.:

Not Divulged

Since How Long Known :

Not Divulged

Maximum Limit Dealt :

Not Divulged

Experience :

Not Divulged

Remark:

Not Divulged

 

 

No. of Employees :

Not Divulged

 

 

Bankers :

Bank Name

Oriental Bank of Commerce

Branch

Ameerpet Branch, Hyderabad – 500016, Telangana, India 

Person Name (With Designation)

Not Divulged

Contact Number

Not Divulged

Name of Account Holder

Not Divulged

Account Number

Not Divulged

Account Since (Date/Year of Account Opening)

Not Divulged

Average Balance Maintained (If Possible)

Not Divulged

Credit Facilities Enjoyed (If any)

Not Divulged

Account Operation

Not Divulged

Remarks (If any)

Not Divulged

 

 

Facilities :

(Rs. In Million)

SECURED LOAN

As on

31.03.2014

As on

31.03.2013

LONG TERM BORROWING

 

 

Term Loan from Bank

11.590

17.262

 

 

 

SHORT TERM BORROWING

 

 

Loan Repayable on Demand

1.171

828.375

 

 

 

Total

12.761

845.637

 

Auditors :

 

Name :

Rathi and Malani

Chartered Accountants

Address :

317, 3rd Floor, Swapnalok, S. D Road, Secunderabad – 500003, Telangana, India

Tel. No.:

91-40-27816017/ 32009337

E-Mail :

rathi_malani@yahoo.com

PAN N Income-tax PAN of auditor or auditor's firm :

ACBPR3959G

 

 

Memberships :

Not Available

 

 

Collaborators :

Not Available

 

 

Associates/Subsidiaries :

Not Available

 

 

CAPITAL STRUCTURE

 

As on 30.09.2014

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

25000000

Equity Shares

Rs.10/- each

Rs. 250.000 Million

 

 

 

 

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

11076411

Equity Shares

Rs.10/- each

Rs. 110.764 Million

 

 

 

 

 

 


 

FINANCIAL DATA

[all figures are in Rupees Million]

 

 

ABRIDGED BALANCE SHEET

 

 

SOURCES OF FUNDS

 

31.03.2014

31.03.2013

31.03.2012

I.              EQUITY AND LIABILITIES

 

 

 

(1)Shareholders' Funds

 

 

 

(a) Share Capital

110.764

110.764

110.764

(b) Reserves & Surplus

405.282

410.208

417.981

(c) Money received against share warrants

0.000

0.000

0.000

 

 

 

 

(2) Share Application money pending allotment

0.000

0.000

0.000

Total Shareholders’ Funds (1) + (2)

516.046

520.972

528.745

 

 

 

 

(3) Non-Current Liabilities

 

 

 

(a) long-term borrowings

561.590

567.262

495.502

(b) Deferred tax liabilities (Net)

82.454

77.179

68.386

(c) Other long term liabilities

650.000

650.000

0.000

(d) long-term provisions

0.000

0.000

0.000

Total Non-current Liabilities (3)

1294.044

1294.441

563.888

 

 

 

 

(4) Current Liabilities

 

 

 

(a) Short term borrowings

887.988

828.375

540.817

(b) Trade payables

116.449

109.560

115.926

(c) Other current liabilities

29.073

28.486

28.843

(d) Short-term provisions

44.419

34.685

30.908

Total Current Liabilities (4)

1077.929

1001.106

716.494

 

 

 

 

TOTAL

2888.019

2816.519

1809.127

 

 

 

 

II.            ASSETS

 

 

 

(1) Non-current assets

 

 

 

(a) Fixed Assets

 

 

 

(i) Tangible assets

623.235

663.401

601.677

(ii) Intangible Assets

15.000

15.000

15.000

(iii) Capital work-in-progress

46.186

45.000

80.626

(iv) Intangible assets under development

0.000

0.000

0.000

(b) Non-current Investments

0.380

0.380

0.380

(c) Deferred tax assets (net)

0.000

0.000

0.000

(d)  Long-term Loan and Advances

0.000

0.000

0.000

(e) Other Non-current assets

680.000

680.000

0.000

Total Non-Current Assets

684.801

1403.781

697.683

 

 

 

 

(2) Current assets

 

 

 

(a) Current investments

0.000

0.000

0.000

(b) Inventories

502.288

391.957

310.716

(c) Trade receivables

806.474

765.110

495.885

(d) Cash and cash equivalents

(5.491)

32.217

67.269

(e) Short-term loans and advances

192.800

197.282

178.338

(f) Other current assets

27.147

26.172

59.236

Total Current Assets

1523.218

1412.738

1111.444

 

 

 

 

TOTAL

2888.019

2816.519

1809.127

 

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2014

31.03.2013

31.03.2012

 

SALES

 

 

 

 

Income

908.530

2059.328

1826.236

 

Other Income

0.000

0.000

0.000

 

TOTAL

908.530

2059.328

1826.236

 

 

 

 

 

Less

EXPENSES

 

 

 

 

Cost of Materials Consumed

749.464

1719.649

1309.590

 

Changes in inventories of finished goods, work-in-progress and Stock-in-Trade

(9.713)

(14.684)

44.285

 

Employees benefits expense

49.181

60.785

75.733

 

Other expenses

31.517

85.883

121.586

 

TOTAL

820.449

1851.633

1551.194

 

 

 

 

 

Less

PROFIT/ (LOSS)  BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION

88.081

207.695

275.042

 

 

 

 

 

Less

FINANCIAL EXPENSES

47.817

170.388

118.010

 

 

 

 

 

 

PROFIT / (LOSS) BEFORE TAX, DEPRECIATION AND AMORTISATION 

40.264

37.307

157.032

 

 

 

 

 

Less/ Add

DEPRECIATION/ AMORTISATION

39.913

36.289

31.332

 

 

 

 

 

 

PROFIT/ (LOSS)  BEFORE TAX

0.351

1.018

125.700

 

 

 

 

 

Less

TAX

5.276

8.791

40.837

 

 

 

 

 

 

PROFIT/ (LOSS)  AFTER TAX 

(4.925)

(7.773)

84.863

 

 

 

 

 

Add

PREVIOUS YEARS’ BALANCE BROUGHT FORWARD 

345.125

352.898

271.866

 

 

 

 

 

Less

APPROPRIATIONS

0.000

0.000

3.831

 

 

 

 

 

 

Balance Carried to the B/S

340.200

345.125

352.898

 

 

 

 

 

 

EARNINGS IN FOREIGN CURRENCY

N.A

284.819

704.341

 

 

 

 

 

 

Earnings / (Loss) Per Share (Rs.)

(0.44)

(0.70)

8.18

 

 

CURRENT MATURITIES OF LONG TERM DEBT DETAILS

 

Particulars

 

31.03.2014

31.03.2013

31.03.2012

Current Maturities of Long term debt

28.133

28.282

28.495

Cash generated from operations

N.A

N.A

N.A

Net cash flow from operating activity

N.A

N.A

N.A

 

 

KEY RATIOS

 

 

PARTICULARS

 

 

31.03.2014

31.03.2013

31.03.2012

Net Profit Margin

(PAT / Sales)

(%)

(0.54)

(0.38)

4.65

 

 

 

 

 

Operating Profit Margin

(PBIDT/Sales)

(%)

9.69

10.09

15.06

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

0.01

0.04

7.27

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.00

0.00

0.24

 

 

 

 

 

Debt Equity Ratio

(Total Debt /Networth)

 

2.86

2.73

2.01

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

1.41

1.41

1.55

 

 

FINANCIAL ANALYSIS

[all figures are in Rupees Million]

 

 

DEBT EQUITY RATIO

 

Particular

31.03.2012

31.03.2013

31.03.2014

 

(Rs. In Million)

(Rs. In Million)

(Rs. In Million)

Share Capital

110.764

110.764

110.764

Reserves & Surplus

417.981

410.208

405.282

Money received against share warrants

0.000

0.000

0.000

 Share Application money pending allotment

0.000

0.000

0.000

Net worth

528.745

520.972

516.046

 

 

 

 

long-term borrowings

495.502

567.262

561.590

Short term borrowings

540.817

828.375

887.988

Current maturities of long-term debts

28.495

28.282

28.133

Total borrowings

1064.814

1423.919

1477.711

Debt/Equity ratio

2.014

2.733

2.864

 

 

 

YEAR-ON-YEAR GROWTH

 

Year on Year Growth

31.03.2012

31.03.2013

31.03.2014

 

(Rs. In Million)

(Rs. In Million)

(Rs. In Million)

Sales

1826.236

2059.328

908.530

 

 

12.764

(55.882)

 

 

NET PROFIT MARGIN

 

Net Profit Margin

31.03.2012

31.03.2013

31.03.2014

 

(Rs. In Million)

(Rs. In Million)

(Rs. In Million)

Sales

1826.236

2059.328

908.530

Profit

84.863

(7.773)

(4.925)

 

4.65%

(0.38)%

(0.54)%

 

 

LOCAL AGENCY FURTHER INFORMATION

 

Sr. No.

Check list by info agents

Available in Report (Yes/No)

1

Year of establishment

Yes

2

Constitution of the entity -Incorporation details

Yes

3

Locality of the entity

Yes

4

Premises details

No

5

Buyer visit details

--

6

Contact numbers

Yes

7

Name of the person contacted

Yes

8

Designation of contact person

Yes

9

Promoter’s background

Yes

10

Date of Birth of Proprietor / Partners / Directors

Yes

11

Pan Card No. of Proprietor / Partners

No

12

Voter Id Card No. of Proprietor / Partners

No

13

Type of business

Yes

14

Line of Business

Yes

15

Export/import details (if applicable)

No

16

No. of employees

No

17

Details of sister concerns

Yes

18

Major suppliers

No

19

Major customers

No

20

Banking Details

Yes

21

Banking facility details

No

22

Conduct of the banking account

--

23

Financials, if provided

Yes

24

Capital in the business

Yes

25

Last accounts filed at ROC, if applicable

Yes

26

Turnover of firm for last three years

Yes

27

Reasons for variation <> 20%

--

28

Estimation for coming financial year

No

29

Profitability for last three years

Yes

30

Major shareholders, if available

Yes

31

External Agency Rating, if available

Yes

32

Litigations that the firm/promoter involved in

--

33

Market information

--

34

Payments terms

Yes

35

Negative Reporting by Auditors in the Annual Report

No

 

MANAGEMENT DISCUSSION AND ANALYSIS:

Incorporated in 1989, Apex Drugs and Intermediates (Apex) having its Registered Office at Hyderabad, is a ISO 9001:2008 certified pharmaceutical company and growing market leader in the bulk drug industry. The goal of Apex is to establish a leadership position in global pharmaceutical industry and in particular Bulk drugs and API industry and deliver international quality product, harnessing the latest technologies at a competitive price with excellent logistic support.

 

UNSECURED LOAN

(Rs. In Million)

Particulars

As on

31.03.2014

As on

31.03.2013

LONG TERM BORROWING

 

 

Term Loan from Bank

550.000

550.000

 

 

 

SHORT TERM BORROWING

 

 

Loan Repayable on Demand

886.817

0.000

 

 

 

Total

1436.817

550.000

 

INDEX OF CHARGES:

S.No.

Charge ID

Date of Charge Creation/Modification

Charge amount secured

Charge Holder

Address

Service Request Number (SRN)

1

10254676

03/09/2013 *

160,000,000.00

ALLAHABAD BANK

INDUSTRIAL FINANCE BRANCH, 6-3-850/3,, SRINIVASA 
PLAZA, 1ST FLOOR, AMEERPET, HYDERABAD- 500018, TELANGANA, INDIA

B84878560

2

10124609

12/09/2008

238,500,000.00

BANK OF INDIA

HYDERABAD CORPORATE BANKING BRANCH, 10-1-1199/2, 
PTI BUILDING, 1ST FLOOR, A.C. GAURDS, HYDERABAD- 500004, TELANGANA, INDIA

A47598933

3

90262254

02/04/2013 *

665,400,000.00

STATE BANK OF INDIA

COMMERCIAL BRANCH, MID CORPORATE GROUP, ASHOK MYH 
OME CHAMBERS, S. D. ROAD, SECUNDERABAD- 500003, TELANGANA, INDIA

B73997595

4

90118429

16/07/1992

4,000,000.00

STATE BANK OF INDIA

MAIN BRANCH, HYDERABAD, TELANGANA, INDIA

-

5

90118343

14/11/1990

780,000.00

STATE BANK OF INDIA

MAIN BRANCH, SECUNDERABAD, TELANGANA, INDIA

-

 

FIXED ASSETS

  • Land
  • Buildings
  • Plant and equipment
  • Other plant and equipment
  • Furniture and fixtures
  • Vehicles
  • Office equipment
  • Computer equipments

 

 

CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No records exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                                       None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                        None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                        None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.66.43

UK Pound

1

Rs.102.40

Euro

1

Rs.75.04

 

 

INFORMATION DETAILS

 

Information Gathered by :

SVA

 

 

Analysis Done by :

TRI

 

 

Report Prepared by :

RKI


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

4

PAID-UP CAPITAL

1~10

3

OPERATING SCALE

1~10

3

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

3

--PROFITABILITY

1~10

2

--LIQUIDITY

1~10

3

--LEVERAGE

1~10

3

--RESERVES

1~10

3

--CREDIT LINES

1~10

3

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

NO

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

DEFAULTER

 

 

--RBI

YES/NO

NO

--EPF

YES/NO

NO

TOTAL

 

27

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.